The tweet was deleted by the author.
But we saved everything 🙂.
Zymeworks will present preclinical data on ZW1953 after stock ends session up 4.1%
Zymeworks will present preclinical data on its new CD3 multispecific T cell engager, ZW1953, at the 2026 American Society of Hematology Annual Meeting. The stock is up 4.1% on the day at $30.13.
Highlights
- Zymeworks will present preclinical data on its new CD3 multispecific T cell engager ZW1953 at the 2026 American Society of Hematology Annual Meeting.
- Shares of Zymeworks are up 4.1% on the day at $30.13.
- All 52 covering analysts rate Zymeworks stock a buy, with a median price target of $38, 26.1% above current levels.
Zymeworks will present at the 2026 American Society of Hematology Annual Meeting. The company plans to share preclinical data on ZW1953 during the event. ZW1953 is described as a CD3 multispecific T cell engager designed to target FLT3, CLEC12A, and CD33 with conditional CD28 co-stimulation for AML.
View post on X Loading...
Bullish chart structure as price gaps higher and nears resistance
A gap up at the open from the previous close of $28.93 to $29.38 set the tone for Zymeworks stock in the session. The price is holding above its MA-20, MA-50, and MA-200, with the daily chart structure remaining bullish. The nearest resistance is the weekly high at $30.38. RSI at 67.8 is nearing overbought territory, which is an early sign the advance is getting stretched.
Upside odds hold well above downside as traders watch $30.38
To gauge whether the latest move will be sustained, traders are focusing on a potential close above the weekly high at $30.38. The session began with an upward gap from $28.93 to $29.38, reflecting strong early buying interest. From here, the upside probability over the next five trading days is more than 80% and the downside probability is less than 20%, with the expected trading range between $29.18 and $31.07. Despite an emerging move higher over the past week that is not yet confirmed, a close above $30.38 would show buyers are willing to follow through, while a drop below $28.27 would indicate the move is being faded. On the weekly chart the longer-term picture stays firmly constructive.
Previously it was reported that Zymeworks secured a major global licensing deal with Roche, marking a shift in the company’s trajectory and technical outlook. The latest unveiling of preclinical progress for ZW1953 adds a new dimension to the narrative, with traders now focused on whether shares can confirm momentum with a sustained close above $30.38 as the next technical inflection point.
This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Subscribe to TU news
Did you like the article?
Top News
Top 5 companies for you
United States
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
Live News
